A prospective open labelled, single arm, non-randomized, single centric, phase II clinical trial to determine the effectiveness of PIRAPPAN KIZHANGU KUDINEER in the management of UTHIRAVATHA SURONITHAM (RHEUMATOID ARTHRITIS)

This is a prospective open labelled, single arm, non-randomized, single centric,  PHASE II  ,clinical trial to determine the effectiveness of PIRAPPAN KIZHANGU KUDINEER in the management of UTHIRAVATHA SURONITHAM (RHEUMATOID ARTHRITIS). After purifcation of trial drug, Pirappan kizhangu kudineer will be prepared and administered at the dosage of 60ml twice a day orally for 48 days for 40 patients (20 OP and 20 IP patients). The primary outcome will be to evaluate the therapeutic effectiveness of siddha herbal Pirappan kizhangu kudineer in the management of Uthiravatha suronitham (Rheumatoid arthritis). The secondary outcome will be to collect various siddha literatures and ,modern journals for literature review of Uthiravatha suronitham, to perform physicochemical, phytochemical, biochemical analysis of Pippan kizhangu kudineer,to evaluate safety profile for acute toxicity of Pirappan kizhangu kudineer, to evaluate pharmacological activities of Pirappan kizhangu kudineer,to study other co factors releated to disease like age,sex,dietary habits, family history and socioeconomic status , to evaluate siddha parameters (including envagai thervu) for uthiravatha suronitham, to evaluate modern parametric changes,to assess the quality of life  of uthiravatha suronitham patients,to document bio statistical analysis.